Describe the proportion of patients in whom the therapies are effective and whether we see durable responses in them as in sometimes the case with immune checkpoint inhibitors in other types of cancers.

Immunotherapy response prediction in gynaecological cancers

Describe the proportion of patients in whom the therapies are effective and whether we see durable responses in them as in sometimes the case with immune checkpoint inhibitors in other types of cancers.

Discuss the problem of current conventional response to immunotherapy prediction markers and the need to find novel ones that may enable more patients to benefit from immunotherapy as well as filtering the ones that may not benefit from immunotherapy.

Suggested tables in the manuscript:

1. list of immunotherapy agents by cancer type with listed studies, summarized results (e.g. ORR, number of patients) and mentioned any inclusion criteria including markers of response that respresented inclusion criteria (e.g. MMR status, MSI status etc.)

2. list of novel, emerging biomarkers studied with summary of marker type, correlation with clinical and histopathological data and conventional biomarkers.